Physician profile
Edwin G Robinson
NPI 1306841564
$83,244.31
in general payments reported to CMS, 2019-2025
66 companies · $2,619 in 2025
The $2,619 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,660 · 2020: $16K · 2021: $33K · 2022: $19K · 2023: $4,335 · 2024: $3,510 · 2025: $2,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,321 · Consulting Fee: $1,900 · Travel and Lodging: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,320.65 |
| Consulting Fee | $1,900.00 |
| Travel and Lodging | $243.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $71,289.08 | 2019-2024 | Gilenya, Mayzent |
| Astrazeneca Pharmaceuticals LP | $2,243.18 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,462.73 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $981.10 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $868.10 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $811.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $511.40 | 2024-2025 | Voquezna |
| Pfizer INC. | $457.32 | 2019-2025 | |
| Abbott Laboratories | $376.57 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.24 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $316.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $293.99 | 2022-2024 | Adlarity, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $282.32 | 2019-2022 | |
| Esperion Therapeutics, INC. | $265.85 | 2021-2025 | Nexletol, Nexlizet |
| Sumitomo Pharma America, INC. | $221.89 | 2023-2024 | Gemtesa |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.